Pulmatrix, Inc. (PULM)
NASDAQ: PULM · Real-Time Price · USD
4.815
-0.055 (-1.12%)
Oct 29, 2025, 11:21 AM EDT - Market open
Pulmatrix Revenue
Pulmatrix had revenue of $3.00K in the twelve months ending September 30, 2025, down -99.97% year-over-year. In the year 2024, Pulmatrix had annual revenue of $7.81M with 6.96% growth.
Revenue (ttm)
$3.00K
Revenue Growth
-99.97%
P/S Ratio
5,928.88
Revenue / Employee
$1,500
Employees
2
Market Cap
17.59M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.81M | 508.00K | 6.96% |
| Dec 31, 2023 | 7.30M | 1.23M | 20.21% |
| Dec 31, 2022 | 6.07M | 902.00K | 17.45% |
| Dec 31, 2021 | 5.17M | -7.47M | -59.09% |
| Dec 31, 2020 | 12.63M | 4.72M | 59.72% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PULM News
- 13 days ago - Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets - PRNewsWire
- 3 months ago - Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets - PRNewsWire
- 5 months ago - Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets - PRNewsWire
- 6 months ago - PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM - Business Wire
- 7 months ago - Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - PRNewsWire
- 1 year ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - Accesswire
- 1 year ago - Pulmatrix and Cullgen Announce Proposed Merger - PRNewsWire
- 1 year ago - Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire